Vinnytsia Regional Clinical Hospital, Ukraine
Vasyl Kishchuk is awarded the title of Professor of the Department of Otorhinolaryngology at Vinnitsa National Medical University n.a. M. Pirogov. He is a highly qualified specialist who conducts up to 800 surgical procedures per year, advises about 5000 patients at various hospitals in Vinnitsa and Vinnitsa region. Scientific work of the department under the direction of professor Kishchuk V. Is dedicated to the problems of chronic tonsillitis, scleroma, endoscopic microsurgery, aesthetic surgery, pathology of the middle ear, nose and white-faced cavities, and improving of the treatment of patients with frontal-basal trauma of the skull. He is also the author and co-author of scientific publications, including textbooks for otolaryngology for students and interns, has 19 innovative proposals, 9 inventions. He constantly introduces new methods of surgical interventions on ENT organs. Vasyl as a talented teacher, doctor and scientist, enjoys a well-deserved authority among the staff of the department, university, students, doctors of Ukraine.
Background and aims: In the light of discussions regarding possible therapies of patients affected by a moderate recurrent tonsillitis (RT), for whom recent clinical guidelines recommend a watchful waiting period, the current clinical trial was performed. It assessed the effectiveness and safety of the homeopathic medicinal product SilAtro-5-90 in patients with moderate RT. The open-label randomized clinical trial was conducted in Germany, Spain and Ukraine in patients aged 6-60 years with moderate RT. The combined treatment of SilAtro-5-90 (Atropinum sulfuricum D5, Hepar sulfuris D3, Kalium bichromicum D4, Silicea D2, Mercurius bijodatus D8) and symptomatic medication (test group) was compared to symptomatic medication alone (control group). SilAtro-5-90 was given during 3 treatment periods of 8 weeks each. Endpoints were the mean period between consecutive acute throat infections (ATI) within 1 year (analysed via repeated events analysis), the number of days the patients were suffering from RT symptoms as well as the incidence of adverse events (AEs). Trial results indicate that SilAtro-5-90 may be a well-tolerated and effective therapeutic option in the treatment of moderate.